TheEdgeResearch
Home / Stocks / PSYGF

Psyence Group Inc. (PSYGF)

OTC Healthcare Drug Manufacturers - General
$0.14 ▲ +9.76%
Market Cap
$2.2M
Sector
Healthcare
Industry
Drug Manufacturers - General
Beta
1.31
52-Wk Range
0.0992-0.1394
CEO
Jody Aufrichtig
Country
CA
Currency
USD

Psyence Group Inc. operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $0.14, up 9.76% on the session, giving a market capitalisation of $2.2M. On trailing twelve-month figures it carries a trailing P/E of -0.21, a net margin of 0.0%. Its beta of 1.31 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.21
Price / Sales
0.00
Price / Book
4.53
EV / EBITDA
-0.23
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
5.95
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
0
IPO date
2022-05-31
Headquarters
Toronto, ON, CA
About Psyence Group Inc.

Psyence Group, Inc. is a life science biotechnology company, which engages in the research, cultivation, and production of psychedelics and nature-based compounds to treat psychological trauma in the context of palliative care and in support of mental wellness. Its divisions include Psyence Production and Psyence Therapeutics. The company was founded by Jody Aufrichtig on March 26, 1994 and is headquartered in Toronto, Canada.

Comparable companies

Psyence Group Inc. is most often compared with the following Healthcare names:

ADXSANTCFCRYMGENPFIGEXKAYSKOANNMLSFRNUGFTLLTF
More research on PSYGF
PSYGF technical analysis PSYGF TheEdge Score Compare against peers
Open full interactive analysis & DCF →